- Home
- SNTG vs XBIO Comparison
SNTG vs XBIO Comparison
Compare SNTG & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNTG | XBIO |
|---|---|---|
| Founded | 2009 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNTG | XBIO |
|---|---|---|
| Price | $2.17 | $2.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.3K | ★ 25.7K |
| Earning Date | 12-19-2025 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $107,507.00 | ★ $2,858,935.00 |
| Revenue This Year | N/A | $1.99 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.30 |
| 52 Week Low | $1.43 | $1.90 |
| 52 Week High | $12.70 | $13.93 |
Technical Indicators
Market Signals| Indicator | SNTG | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 40.27 |
| Support Level | $2.10 | $2.21 |
| Resistance Level | $2.45 | $2.69 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 46.67 | 1.49 |
Price Performance
Historical ComparisonAbout SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.